Phaseline

Companies › Shanghai Novamab Biopharmaceuticals

Shanghai Novamab Biopharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LQ036
Single-domain antibody
–Phase 2AsthmaSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07589439LQ036Phase 2AsthmaRespiratorySep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Uniquity One (UNI) Arcturus Therapeutics Direct Biologics Mannkind Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.